A Rollover Study for Patients Who Participated in Other Romidepsin Protocols

PHASE2CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

May 1, 2011

Primary Completion Date

September 5, 2012

Study Completion Date

September 5, 2012

Conditions
LymphomaCancer
Interventions
DRUG

Romidepsin

The participants will generally continue at the same dose, infusion time and frequency used for the last dose of romidepsin given in the preceding romidepsin study. If the participant entered this rollover study in the middle of a cycle, then the cycle number and cycle day will be carried over from the preceding romidepsin study.

Trial Locations (3)

34232

Florida Cancer Specialists, Sarasota

37203

Sarah Cannon Research Institute, Nashville

W1G6AD

Sarah Cannon Research UK, London

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

Celgene Corporation

INDUSTRY

lead

Celgene

INDUSTRY